Unveiling the gap of heart failure: a DATASUS study

Vivian Cardoso Batista¹*, Renato Lima Vitorasso², Vicky Nogueira-Pileggi², Renato Mantelli Picoli², Elizabeth Bilevicius¹

¹ Research, Development and Medical Affairs, Viatris, Sao Paulo, SP, Brazil

² Oracle Life Sciences

*Corresponding author

Vivian.batista@viatris.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Heart failure (HF) decompensation is the main cause of hospitalizations in developed countries. In Brazil, it represents the third general cause. Aiming to analyze the treatment journey for different types of HF in Brazil, the present study seeks to define a flowchart and clinical rationale that covers the procedures (and their respective frequency) in patients with HF in the Brazilian Unified Health System (SUS) included in DATASUS database. By doing so, the final objectives were: a) To identify potential patients with HF to present an estimate of the underreporting of the disease in the country; b) To describe the estimated mortality of potential patients with HF in Brazil. We used data from DATASUS, which encompasses information from the Brazilian Unified Health System (SUS). Specifically, we utilized the SUS-SIM (Mortality Information System) and SUS-SIA (Ambulatory Information System). Results: According to the data, we had a potential missing of patients with HF of 54,000 patients per year at diagnosis and 200,000 deaths that could lead to HF (both sexes). Considering the sensitivity analysis when there was a 20% underestimation in the number of potential HF cases, the underestimation rate of cases diagnosed with HF was 12%. We also found that when there was an underestimation of 40% in potential cases of death due to HF, there was an average underestimation of 41% in cases of death diagnosed as HF. The results highlight the importance of accurate diagnosis and a comprehensive approach to identifying potential cases of HF to improve the recording and management of this condition. Underestimation of these cases may have significant implications for public health and clinical management of HF emphasizing the need for strategies to increase early detection and adequate case recording. The next steps would be how much this underestimation impacts the public health in Brazil, particularly in terms of financial resources.
Key words: heart failure, public health,

Introduction

According to the World Health Organization (WHO), cardiovascular diseases (CVD) are a group of diseases whose majority can be prevented through a behavioral approach, which represent the main cause of deaths worldwide. It is estimated that 17.9 million people in 2019 died from CVD, representing 32% of all deaths globally(1).

Heart failure (HF) stands out as a highly prevalent condition among CVDs, presenting high morbimortality rates. It has been estimated that HF alone affected 23 million people in 2017, with a projected increase of around 46% by 2030 (3). HF is defined as a clinical syndrome with symptoms and/or signs caused by structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptides and/or objective evidence of pulmonary or systemic congestion(2).

In Brazil, between 2008 and 2018, HF was the main cause of hospitalizations for CVD with more than 2 million hospitalizations having been recorded and more than 252 thousand deaths. The risk of developing HF is directly proportional to aging. Even though the prevalence is higher among elderly, an increase in prevalence of this condition in the 50-year-old group is being observed. This high hospitalization and mortality rates were responsible for health services expenses that exceeds 3 billion Brazilian Reais (626.5 million US Dollars) only in 2019(3).

HF decompensation is the main cause of hospitalizations in developed countries. In Brazil it represents the third general cause (4). Furthermore, it is believed that there is a high rate of underdiagnosis due to the presence of other comorbid diseases that can be diagnostic confounding factors, especially in cases were HF presents with mild symptoms.
According to the Brazilian Chronic Heart Failure Treatment Guideline, the patient's prognosis does not depend on the HF subtype and is worse compared to the general population(5). Even though it was observed a decrease in hospitalizations due to HF during the last decade, the number of deaths remained stable. It is important to highlight that mortality rates are possibly underestimated since more than 50% of HF patients experience sudden death. (6).

Aiming to analyze the treatment journey for different types of HF in Brazil, the present study seeks to define a flowchart and clinical rationale that covers the procedures (and their respective frequency) in patients with HF in the Brazilian Unified Health System (SUS) included in DATASUS database. By doing so, the final objectives were:

a) To identify potential patients with HF to present an estimate of the underreporting of the disease in the country.

b) To describe the estimated mortality of potential patients with HF in Brazil.

Materials and Methods

We sought to understand in the literature the patient journey in Brazil. In this study, we employed data from DATASUS, which encompasses information from the Brazilian Unified Health System (SUS). Specifically, we utilized the SUS-SIM (Mortality Information System) and SUS-SIA (Ambulatory Information System). The data from these systems are accessible to the public via FTP in .dbc format, and the SIA-SUS data were converted to .parquet. Both data extraction and variable calculations were conducted in a computational environment using R (version 4.2.0) and Python (version 3.10.6). There was no need to seek the approval of an institutional review board before the study began. As previously stated, all the human
participants information utilized in this study was obtained through the DATASUS database, a publicly available dataset of the public health system in Brazil. Furthermore, All the data contained in the DATASUS database is fully anonymized when it comes to patients’ personal information. Therefore, no ethical approval or consent was needed. The data utilized was accessed and extracted on September 12th 2023. In this section, we present flowcharts delineating the inclusion criteria for the subgroups under study. This was elaborated according to cardiology specialists regarding patient journey.

**Fig 1 - Flowchart to be carried out to find underreported patients by ICD and procedure**

![Flowchart](image)

**Fig 2 - Flowchart to find underreported patients regarding mortality to be carried out in the next step. HF = heart failure. HF = heart failure**
The inclusion criteria varied according to the group to be studied in the present project. 

The study interval of the present work is highlighted as being from 2018 to 2022 (However, since the patient may have had their HF record or potential HF classification prior to 2018, 3 previous years were included in the extraction to obtain the cut-off without a bias towards the classification of the first years).

1) All those who had at least one record of ICD I50 in any APAC (Ambulatory Procedure Authorization) of DataSUS-SIA were classified as patients with HF.

2) all those deaths that had an ICD I50 note on the death certificate in the base cause, or lines A, B, C, D and II, were classified as HF-related deaths.

3) all those who complied with the flowchart in Fig. 1 and did not have an ICD I50 record were classified as potential patients with HF.
4) Finally, all those who were marked as such in Fig. 2 and did not have an ICD I50 record on the certificate were identified as potential deaths related to HF. It is worth noting that the ICDs indicated in the figure above was searched in all available fields on the death certificate, except for the underlying cause. Additionally, the cause of death had the following subclassifications:

a) Cardiomyopathies, valvular heart disease, valvular heart disease.

b) Heart attack and ischemic diseases.

**Sensitivity Analysis**

We use as Underestimation rate the following equation:

\[ \text{Underestimation rate} = \frac{\text{potential number}}{\text{potential + confirmed numbers}} \quad \text{equation 1} \]

where this rate was applied for both cases and number of deaths. The deterministic sensitivity analysis was conducted to assess the rate of underestimation in A) ambulatorial diagnoses and B) deaths related to heart failure (HF) over the studied time interval. This analysis involves considering values ranging from 0% to 100% (0%, 20%, 40%, 60%, 80%, 100%) as the proportion of potential patients or deaths that are correctly identified as actual patients or deaths related to HF. For instance, when determining the underestimation rate for deaths, assuming 20% of potential patients are correctly identified as actual heart failure (HF) patients, the calculation follows this equation:

\[ \text{Underestimation rate} = \frac{\text{potential number of HF deaths} \times 20\%}{\text{potential number of HF deaths} \times 20\% + \text{confirmed deaths}} \quad \text{equation 2} \]

This approach facilitates a thorough investigation into the influence of different proportions of potential patients accurately classified as HF patients on underestimation rates.
Results

Population characteristics

Table 1 shows the description of the population separated by patients with a diagnosis of HF and potential HF patients during the years of 2018 to 2022. Table 2 shows the description of patients confirmed deaths by HF and those with other types that are potentially HF patients.

Table 1. Description of the population of confirmed patients and potential cases of HF.

<table>
<thead>
<tr>
<th></th>
<th>Age at diagnosis (years)</th>
<th>Male n (%)</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>57.25 ± 21.35</td>
<td>32,674.00</td>
<td>(45.19)</td>
</tr>
<tr>
<td>2019</td>
<td>57.83 ± 21.33</td>
<td>35,637.00</td>
<td>(46.02)</td>
</tr>
<tr>
<td>2020</td>
<td>59.86 ± 19.75</td>
<td>30,663.00</td>
<td>(47.98)</td>
</tr>
<tr>
<td>2021</td>
<td>60.26 ± 19.16</td>
<td>44,431.00</td>
<td>(48.91)</td>
</tr>
<tr>
<td>2022</td>
<td>61.15 ± 18.18</td>
<td>62,291.00</td>
<td>(50.58)</td>
</tr>
<tr>
<td>Potential HF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>61.02 ± 14.55</td>
<td>26,462.00</td>
<td>(53.74)</td>
</tr>
<tr>
<td>2019</td>
<td>61.94 ± 14.06</td>
<td>28,810.00</td>
<td>(54.71)</td>
</tr>
<tr>
<td>2020</td>
<td>62.45 ± 13.41</td>
<td>23,556.00</td>
<td>(55.29)</td>
</tr>
<tr>
<td>2021</td>
<td>62.48 ± 13.96</td>
<td>28,139.00</td>
<td>(55.19)</td>
</tr>
<tr>
<td>2022</td>
<td>62.66 ± 14.49</td>
<td>28,136.00</td>
<td>(54.79)</td>
</tr>
</tbody>
</table>

Table 2. Description of confirmed patient deaths and potential HF-related deaths.

<table>
<thead>
<tr>
<th></th>
<th>Age on day of death (years)</th>
<th>Male n (%)</th>
<th>Number of deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>74.68 ± 17.42</td>
<td>53,239.00</td>
<td>(49.10)</td>
</tr>
<tr>
<td>2019</td>
<td>74.88 ± 17.14</td>
<td>53,935.00</td>
<td>(49.14)</td>
</tr>
<tr>
<td>2020</td>
<td>74.79 ± 15.98</td>
<td>58,719.00</td>
<td>(49.83)</td>
</tr>
<tr>
<td>2021</td>
<td>74.88 ± 16.02</td>
<td>65,535.00</td>
<td>(49.65)</td>
</tr>
<tr>
<td>2022</td>
<td>75.36 ± 16.41</td>
<td>64,342.00</td>
<td>(48.96)</td>
</tr>
<tr>
<td>Potential HF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2018</td>
<td>70.75 ± 21.57</td>
<td>105,724.00</td>
<td>(56.28)</td>
</tr>
</tbody>
</table>
Fig 3 shows the absolute number of deaths related to potential cases of HF, stratified by "proxy" ICDs, specifically cardiomyopathies and heart attacks and ischemia, which are conditions that make up potential cases of HF. From an analysis of the figure, it is evident that most deaths associated with potential HF cases are attributed to cases of heart attacks and ischemia, representing approximately 180,000 to 200,000 cases, which is equivalent to approximately 98% of potential HF cases. Furthermore, it is possible to observe a slight increase in the number of deaths from the year 2021 onwards.

**Fig. 3.** Total number of deaths of patients classified as potential patients with HF divided into the following groups: 1) Cardiomyopathy, valvular heart disease and valvular heart disease; and 2) Ischemia and heart attacks.

<table>
<thead>
<tr>
<th>Year</th>
<th>Mean ± SD</th>
<th>Number of Deaths</th>
<th>Cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>70.97 ± 21.16</td>
<td>107,688.00 (56.20)</td>
<td>191,612</td>
</tr>
<tr>
<td>2020</td>
<td>71.30 ± 19.20</td>
<td>110,659.00 (57.01)</td>
<td>194,111</td>
</tr>
<tr>
<td>2021</td>
<td>71.12 ± 19.07</td>
<td>120,797.00 (56.55)</td>
<td>213,606</td>
</tr>
<tr>
<td>2022</td>
<td>71.47 ± 19.52</td>
<td>113,179.00 (56.19)</td>
<td>201,418</td>
</tr>
</tbody>
</table>

**Fig 4.** Sensitivity analysis of the rate of underestimation of A) ambulatorial diagnosis and B) deaths related to HF over the time interval studied. The sensitivity analysis will be...
carried out considering values from 0% to 100% (0; 20; 40; 60; 80; 100%) as the proportion of potential patients/deaths as actual patients/deaths related to HF. Example, to calculate the underestimation rate of deaths at 20%: (potential number of deaths related to HF * 20%) / (potential number of deaths related to HF * 20% + number of deaths with I50 registration).

A)

Fig 4A presents the representation of the percentage of underestimation of the ambulatorial patients, while Fig 4B shows the percentage of underestimation of the number of
deaths of these patients during the 5-year period. In Fig 4A, it is notable that when there was a
20% underestimation in the number of potential HF cases, the underestimation rate of cases
diagnosed with HF was 12%. To illustrate another example, when there was an underestimation
of 80% in potential HF cases, the underestimation of the number of cases diagnosed with HF
reached 35%. Variations were observed from the year 2021 onwards. Similar results can be seen
in Fig 4B in relation to deaths due to HF. When there was an underestimation of 40% in potential
cases of death due to HF, there was an average underestimation of 41% in cases of death
diagnosed as HF. In the case of all potential patients deaths were actually HF cases,
approximately 63% of the number of deaths diagnosed as HF were also underestimated.

Discussion

To the best of our knowledge, this is the first article using public database of Brazil to
hypothesize about the misdiagnosis of heart failure and the mortality burden of this disease. It is
well known that HF is a common syndrome that represents the end stage of several heart
diseases. Decompensation is the main cause of hospitalizations in developed countries and in
Brazil it is the third general cause of hospitalization(4). With the strong possibility that many cases
of hospitalizations due to HF are underreported because they are associated with other
pathologies especially in cases were HF presents with mild symptoms, we create a flowchart to
understand this phenomenon.

In our study, the cases of HF were similar between men and women, with a slightly
inclination for cases of men in the potential cases. We also found an increase on number of deaths
in the studied timeline. This phenomenon could be because aging is a significant factor in the
development and progression of heart failure, with the risk increasing as individuals grow older(7)
or due to increased number of diagnosis of the disease(8). It is important to stat that the COVID-
19 during 2020 contributed to lower numbers in all diseases around the world including HF. The decrease in hospitalizations for non-COVID-19 reasons appears to be linked to hospital overcrowding during periods of COVID-19 surges, coupled with reduced demand for healthcare from individuals concerned about contracting the virus.

In 2016 a systematic review analyzed the burden of HF in Latin America countries. The study included 143 studies of which 64% were in Brazil, pointing to an incidence of the disease of 199 cases per 100,000 persons-years. The mean percentage of men was 61.07% ±11.48% with a mean age of 60.34± 8.98 years. Our study showed that the actual diagnosis of HF was in similar age for both HF and potential (around 59 years and 61 years, respectively) with most men in the potential and equal in actual patients with HF.

It is important to emphasize that our study used data from ambulatory patients, and our study did not show the prevalence of the disease once the patients who seek primary care in the public health care system were the ones studied. This gives us reason to infer that the patients flagged as potential HF cases were in fact cases of HF. That was also the reason we performed a sensitivity analysis that showed that even smaller number of 20% as potential HF, the underestimation of actual ambulatory cases is 12%.

A study published in 2021 by Wong et al have already highlighted to the relevance of HF misdiagnosis. In the review, misdiagnosis ranges from 16.1% in the case of patients discharged from hospital with a diagnosis of HF to 68.5% from general practitioner referrals for HF who do not have left ventricular dysfunction, valvular heart disease, or atrial fibrillation. These findings suggests that one of the main reasons for misdiagnosis could be the presence of less severe symptoms. This was the same assumption of our study.

HF is frequently misdiagnosed due to several factors inherent in its presentation and clinical assessment. Firstly, HF symptoms such as shortness of breath, fatigue, and edema
can overlap with those of other cardiovascular and respiratory conditions, leading to diagnostic ambiguity(13). Moreover, the clinical manifestations of HF may vary widely among patients, making it challenging to recognize consistently across different individuals. Additionally, healthcare providers may encounter difficulties in interpreting diagnostic tests accurately, especially in cases where imaging and biomarkers yield inconclusive results or where comorbid conditions complicate the diagnostic process(14,15). Ultimately, the misdiagnosis of HF underscores the importance of enhanced clinical awareness, comprehensive evaluation strategies, and continued medical education to improve diagnostic accuracy and optimize patient outcomes. Our data corroborate with this potential HF underestimation diagnosis.

Regarding mortality, we represent in Figure 3 the total of deaths of potential patients with HF. Also in the sensitivity analysis we reported that if there was an underestimation of 40% in potential cases of death due to HF, there was an average underestimation of 41% in cases of death diagnosed as HF. Additionally, we represent the number of deaths in subgroups of diseases such as heart attack and ischemia and cardiomyopathies, showing that there is a predominance in the first subgroup over the second. Almost all deaths flagged as potential HF are from patients with heart attack and ischemia in their main cause. It is well known that heart failure often accompanies other cardiovascular conditions, compounding the risk of adverse outcomes. Early diagnosis, comprehensive management strategies, adherence to treatment plans, and lifestyle modifications play pivotal roles in reducing mortality rates and improving survival outcomes among individuals living with heart failure.

The data of the present study point to an overall increase in HF-related ambulatory patients and mortality and potential HF cases over five years, with some notable fluctuations and significant variations in specific years. Furthermore, the underestimation of potential HF cases potentially impacted the underestimation of diagnosed cases and deaths from HF, highlighting
the importance of an accurate assessment of these data for the effective management of this health condition.

Conclusions

In summary, the results highlight the importance of accurate diagnosis and a comprehensive approach to identifying potential cases of IC to improve the recording and management of this condition. Underestimation of these cases may have significant implications for public health and clinical management of IC, emphasizing the need for strategies to increase early detection and adequate case recording. The next steps would be how much this underestimation impacts the public health in Brazil, particularly in terms of financial resources.

Funding: Viatris

References


